Page 80 - Withrow and MacEwen's Small Animal Clinical Oncology, 6th Edition
P. 80

CHAPTER 2  Tumor Biology and Metastasis  59


             138.   Friedl P, Wolf K, Lammerding J: Nuclear mechanics during cell     162.   Kalluri R: Basement membranes: structure, assembly and role in
               migration, Curr Opin Cell Biol 23:55–64, 2011.        tumour angiogenesis, Nat Rev Cancer 3:422–433, 2003. 
             139.   Friedl P, Wolf K: Plasticity of cell migration: a multiscale tuning     163.   Frisch SM, Francis H: Disruption of epithelial cell-matrix interac-
  VetBooks.ir    140.   Sabeh F, Shimizu-Hirota R, Weiss SJ: Protease-dependent versus     164.   Taddei ML, Giannoni E, Fiaschi T, et al.: Anoikis: an emerging
                                                                     tions induces apoptosis, J Cell Biol 124:619–626, 1994.
               model, J Cell Biol 188 11–19, 2010
                                                                     hallmark in health and diseases, J Pathol 226:380–393, 2012.
               -independent cancer cell invasion programs: three-dimensional
               amoeboid movement revisited, J Cell Biol 185:11–19, 2009.    165.   Grossmann  J: Molecular mechanisms of “detachment-induced
             141.   Scott  RW, Crighton D, Olson MF: Modeling and imaging   apoptosis–Anoikis”, Apoptosis 7:247–260, 2002.
               3-dimensional collective cell invasion, J Vis Exp 58:3525, 2011.    166.   Guo W, Giancotti FG: Integrin signalling during tumour progres-
             142.   Condeelis  J, Segall JE: Intravital imaging of cell movement in   sion, Nat Rev Mol Cell Biol 5:816–826, 2004.
               tumours, Nat Rev Cancer 3:921–930, 2003.            167.   Fosmire SP, Dickerson EB, Scott AM, et al.: Canine malignant
             143.   Condeelis J, Singer RH, Segall JE: The great escape: when cancer   hemangiosarcoma as a model of primitive angiogenic endothelium,
               cells hijack the genes for chemotaxis and motility, Annu Rev Cell   Lab Invest 84:562–572, 2004.
               Dev Biol 21:695–718, 2005.                          168.   Akhtari M, Mansuri J, Newman KA, et al.: Biology of breast cancer
             144.   Wang W, Wyckoff JB, Frohlich VC, et al.: Single cell behavior in   bone metastasis, Cancer Biol Ther 7:3–9, 2008.
               metastatic primary mammary tumors correlated with gene expres-    169.   Restucci B, De Vico G, Maiolino P: Expression of beta 1 integ-
               sion patterns revealed by molecular profiling, Cancer Res 62:6278–  rin in normal, dysplastic and neoplastic canine mammary gland,
               6288, 2002.                                           J Comp Pathol 113:165–173, 1995.
             145.   Wyckoff JB, Segall JE, Condeelis JS: The collection of the motile     170.   Olivry T, Moore PF, Naydan DK, et al.: Investigation of epider-
               population of cells from a living tumor, Cancer Res 60:5401–5404,   motropism in canine mycosis fungoides: expression of intercellular
               2000.                                                 adhesion molecule-1 (ICAM-1) and beta-2 integrins, Arch Derma-
             146.   Jankowski MK, Ogilvie GK, Lana SE, et al.: Matrix metallopro-  tol Res 287:186–192, 1995.
               teinase activity in tumor, stromal tissue, and serum from cats with     171.   Moore PF, Rossitto PV, Danilenko DM: Canine leukocyte inte-
               malignancies, J Vet Intern Med 16:105–108, 2002.      grins: characterization of a CD18 homologue,  Tissue Antigens
             147.   Loukopoulos P, O’Brien T, Ghoddusi M, et al.: Characterisation   36:211–220, 1990.
               of three novel canine osteosarcoma cell lines producing high levels     172.   Selvarajah  GT,  Kirpensteijn  J,  van  Wolferen ME,  et  al.:  Gene
               of matrix metalloproteinases, Res Vet Sci 77:131–141, 2004.  expression profiling of canine osteosarcoma reveals genes associated
             148.   Hirayama K, Yakota H, Onai R, et al.: Detection of matrix metallo-  with short and long survival times, Mol Cancer 8:72, 2009.
               proteinases in canine mammary tumours: analysis by immunohis-    173.   Fukata M, Kaibuchi K: Rho-family GTPases in cadherin-mediated
               tochemistry and zymography, J Comp Pathol 127:249–256, 2002.  cell-cell adhesion, Nat Rev Mol Cell Biol 2:887–897, 2001.
             149.   Lana SE, Ogilvie GK, Hansen RA, et al.: Identification of matrix     174.   Seftor RE, Seftor EA, Gehlsen KR, et al.: Role of the alpha v beta 3
               metalloproteinases in canine neoplastic tissue, Am J Vet Res 61:111–  integrin in human melanoma cell invasion, Proc Natl Acad Sci U S A
               114, 2000.                                            89:1557–1561, 1992.
             150.   Leibman NF, Lana SE, Hansen RA, et al.: Identification of matrix     175.   Zheng DQ, woodard AS, Fornaro M, et al.: Prostatic carcinoma
               metalloproteinases in canine cutaneous mast cell tumors,  J Vet   cell migration via alpha(v)beta3 integrin is modulated by a focal
               Intern Med 14:583–586, 2000.                          adhesion kinase pathway, Cancer Res 59:1655–1664, 1999.
             151.   Coussens LM, Fingleton B, Matrisian LM: Matrix metalloprotein-    176.   Ruoslahti E, Reed JC: Anchorage dependence, integrins, and apop-
               ase inhibitors and cancer: trials and tribulations, Science 295:2387–  tosis, Cell 77:477–478, 1994.
               2392, 2002.                                         177.   Paoli P, Giannoni E, Chiarugi P: Anoikis molecular pathways and
             152.   Coussens LM, Fingleton B, Matrisian LM: Matrix metalloprotein-  its role in cancer progression, Biochim Biophys Acta 1833:3481–
               ase inhibitors and cancer: trials and tribulations, Science 295:2387–  3498, 2013.
               2392, 2002.                                         178.   Nagaprashantha LD, Vatsyayan R, Lalsani PC, et al.: The sensors
             153.   Moore AS, Dernell WS, Ogilvie GK, et al.: Doxorubicin and BAY   and regulators of cell-matrix surveillance in anoikis resistance of
               12–9566 for the treatment of osteosarcoma in dogs: a randomized,   tumors, Int J Cancer 128:743–752, 2011.
               double-blind, placebo-controlled study, J Vet Intern Med 21:783–    179.   Lascelles BD, Dernell WS, Correa MT, et al.: Improved survival
               790, 2007.                                            associated with postoperative wound infection in dogs treated with
             154.   Ramnath N, Creaven PJ: Matrix metalloproteinase inhibitors, Curr   limb-salvage surgery for osteosarcoma, Ann Surg Oncol 12:1073–
               Oncol Rep 6:96–102, 2004.                             1083, 2005.
             155.   Rucci N, Sanita P, Angelucci A: Roles of metalloproteases in meta-    180.   Yu C, Xu S-F, Xu M, et al.: Postoperative infection and survival
               static niche, Curr Mol Med 11:609–622, 2011.          in osteosarcoma patients: reconsideration of immunotherapy for
             156.   Qian BZ, Pollard JW: Macrophage diversity enhances tumor pro-  osteosarcoma, Mol Clin Oncol 3:495–500, 2015.
               gression and metastasis, Cell 141:39–51, 2010.      181.   Smyth MJ, Hayakawa Y, Takeda K, et al.: New aspects of natu-
             157.   Foroni C, Broggini M, Generali D, et al.: Epithelial-mesenchymal   ral-killer-cell surveillance and therapy of cancer, Nat Rev Cancer
               transition and breast cancer: role, molecular mechanisms and clini-  2:850–861, 2002.
               cal impact, Cancer Treat Rev 38:389–397, 2012.      182.   Mocellin S, Rossi CR, Lisa M, et al.: Colorectal cancer vaccines:
             158.   Peinado H, Olmeda D, Cano A: Snail, Zeb and bHLH factors in   principles, results, and perspectives,  Gastroenterology 127:1821–
               tumour progression: an alliance against the epithelial phenotype?   1837, 2004.
               Nat Rev Cancer 7:415–428, 2007.                     183.   Mocellin S, Rossi CR, Nitti D: Cancer vaccine development: on
             159.   Moreno-Bueno G, Peinado H, Molina P, et al.: The morphological   the way to break immune tolerance to malignant cells, Exp Cell Res
               and molecular features of the epithelial-to-mesenchymal transition,   299:267–278, 2004.
               Nat Protoc 4:1591–1613, 2009.                       184.   Rao B, Han M, Wang L, et al.: Clinical outcomes of active specific
             160.   Floor S, van Staveren WC, Larsimont D, et al.: Cancer cells in   immunotherapy in advanced colorectal cancer and suspected mini-
               epithelial-to-mesenchymal transition and tumor-propagating-can-  mal residual colorectal cancer: a meta-analysis and system review,
               cer stem cells: distinct, overlapping or same populations, Oncogene   J Transl Med 9:17, 2011.
               30:4609–4621, 2011.                                 185.   Bergman PJ: Cancer immunotherapy, Vet Clin N Am Small Anim
             161.   Hendrix  MJ, Seftor EA, Hess AR, et  al.: Vasculogenic mimicry   Pract 40:507–518, 2010.
               and tumour-cell plasticity: lessons from melanoma, Nat Rev Cancer     186.   Grosenbaugh DA, Leard AT, Bergman P, et al.: Safety and efficacy
               3:411–421, 2003.                                      of a xenogeneic DNA vaccine encoding for human tyrosinase as
   75   76   77   78   79   80   81   82   83   84   85